Morning Seminar February 27, 2007

Blood. 2007 Jan 1;109(1):306-14.
INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K, Kamitsuji Y, Kawata E, Deguchi Y, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui K, Maekawa T.

Morning Seminar February 22, 2007

WT1 vaccination therapy for pediatric solid tumor

Morning Seminar February 20, 2007

Exp Hematol. 2006 Dec;34(12):1746-52.
Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity.
Bethge WA, Haegele M, Faul C, Lang P, Schumm M, Bornhauser M, Handgretinger R, Kanz L.

Morning Seminar February 15, 2007

J Clin Oncol. 2005 Sep 1;23(25):6172-80.
Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.
Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein ML, Dancey JE, Speights RA, Blaney SM, Croop JM, Reaman GH, Adamson PC; Children's Oncology Group

Morning Seminar February 8, 2007

Biol Blood Marrow Transplant. 2007 Jan;13(1):82-9.
Double unrelated reduced-intensity umbilical cord blood transplantation in adults.
Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E, Haspel R, Kao G, Liney D, Alyea E, Lee S, Cutler C, Ho V, Soiffer R, Antin JH.

Morning Seminar February 6, 2007

ASH2006, Part I